Gisens Biotech is a technology company.
Gisens Biotech has raised $420K across 1 funding round.
Gisens Biotech has raised $420K in total across 1 funding round.
Gisens Biotech is a Berkeley, California-based biotechnology company developing next-generation, graphene-based biosensors for point-of-care diagnostics, targeting patients with chronic diseases like kidney disease.[1][2][3] Their core product, G-LoC, is a reagent-free, home-use device that analyzes samples such as saliva in minutes with over 95.5% accuracy, detecting biomarkers without labs or logistics to enable faster clinical decisions.[2][3] It serves patients and doctors managing chronic conditions, solving the problem of slow, inaccessible testing by delivering ultrasensitive, low-cost results from a single drop—10-fold more sensitive than lateral flow assays with 99.8% predictive value and 100% sensitivity.[1][2] The company has raised funding from accelerators like Techstars Physical Health and Berkeley SkyDeck, showing early validation and growth momentum through pilots like Roche-funded kidney disease monitoring.[1][2]
Founded in 2018 (with some sources noting 2019), Gisens Biotech emerged from the labs of UC Berkeley, where co-founders Luis Pierpauli (CEO, MD from University of Buenos Aires, entrepreneur), Esteban Piccinini (CTO), and Omar Azzaroni developed a novel, industrial-scale method for producing low-cost graphene biosensors.[1][5] The idea stemmed from harnessing graphene nanotechnology—coupled with biorecognition elements like enzymes and antibodies—to create label-free sensors for ultrasensitive biomarker detection outside clinical settings.[1] Early traction included Techstars acceleration, Berkeley SkyDeck investment, and real-world validation of a COVID-19 biosensor, paving the way for chronic disease applications like at-home kidney monitoring.[1][2]
Gisens Biotech rides the wave of decentralized healthcare and point-of-care diagnostics, accelerated by COVID-19's demand for rapid, at-home testing amid rising chronic disease burdens like kidney failure.[2] Timing aligns with nanotechnology maturation—graphene's commercialization enables ultrasensitive, affordable biosensors just as aging populations and telemedicine boom strain traditional labs.[1][3] Market forces favoring them include regulatory pushes for home diagnostics, falling sensor costs, and investor interest in biotech hardware (e.g., Techstars, SkyDeck backing).[1] They influence the ecosystem by pioneering graphene in consumer health, potentially disrupting $100B+ diagnostics markets and enabling AI-driven personalized medicine through real-time biomarker data.[2][3]
Gisens Biotech is poised to scale G-LoC beyond kidney disease into multi-biomarker panels for diabetes, cardiovascular, and oncology monitoring, leveraging Roche pilots and accelerator networks for partnerships and FDA pathways.[2] Trends like AI biomarker analysis, wearable integration, and global chronic care shortages will propel them, with graphene's edge ensuring cost leadership in a crowded POC field. Their influence could evolve from niche innovator to platform provider, empowering proactive healthcare and redefining chronic disease management from reactive to predictive. This positions them as a key player in nanotechnology's biotech revolution, fulfilling their mission to bring lab-grade diagnostics home.[1][3]
Gisens Biotech has raised $420K in total across 1 funding round.
Gisens Biotech's investors include Alumni Ventures, Berkeley SkyDeck Fund, BootstrapLabs, Xuhui Shao, GRID EXPONENTIAL, R42 Group, Seven Seven Six, SOSV.
Gisens Biotech has raised $420K across 1 funding round. Most recently, it raised $420K Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $420K Seed | Alumni Ventures, Berkeley SkyDeck Fund, BootstrapLabs, Xuhui Shao, GRID EXPONENTIAL, R42 Group, Seven Seven Six, SOSV |